Assessment of nanOss Bioactive 3D in the Posterolateral Spine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01829997|
Recruitment Status : Active, not recruiting
First Posted : April 11, 2013
Last Update Posted : February 7, 2018
Spine fusion is one of the most common procedures performed in spinal surgery. Several surgical techniques can achieve a solid union, but the intertransverse posterolateral fusion (PLF) is the most widely used. However, complications can develop when the bone graft material used is insufficient to achieve the desired fusion. With its unique properties, nanOss Bioactive 3D can be mixed with bone marrow aspirate (BMA) and autograft bone to obtain new bone growth during the healing process.
nanOss Bioactive 3D is approved for use in the U.S., however, additional information is useful to assess its efficacy in the posterolateral spine. The purpose of this study is to assess fusion results in the posterolateral spine using nanOss Bioactive 3D mixed with autograft bone and BMA. It is hypothesized that the use of nanOss Bioactive 3D will result in fusion at 12 months, with CT evidence of bridging trabecular bone, less than 3mm of translational motion, and less than 5 degrees of angular motion.
|Condition or disease||Intervention/treatment||Phase|
|Degenerative Disc Disease Spinal Stenosis Spondylolisthesis||Device: nanOss Bioactive 3D BVF||Not Applicable|
The post market clinical investigation is designed to assess instrumented PLF using nanOss Bioactive 3D bone void filler with autograft bone and bone marrow aspirate in patients with symptomatic spinal stenosis secondary to degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at one or two adjacent levels from L2-S1 characterized by the inclusion and exclusion criteria.
Patients will be evaluated at Preop, discharge, 6 and 12 months. X-rays will be obtained at each visit; Additionally, a CT scan will be performed at the 12 month postoperative visit to assess fusion status.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Post-Market Assessment Of NanOss Bioactive 3D in the Posterolateral Spine|
|Study Start Date :||April 2013|
|Estimated Primary Completion Date :||April 2018|
|Estimated Study Completion Date :||April 2018|
Experimental: nanOss Bioactive 3D BVF
Bilateral, instrumented posterolateral fusion surgery where nanOss Bioactive 3D will be hydrated with autologous BMA and placed bilaterally on a bed of local autograft bone spanning the transverse processes of the treated segment. If an interbody fusion is performed, only a PLIF or TLIF with PEEK IBF devices may be performed.
Device: nanOss Bioactive 3D BVF
nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
- Number of patients with fusion [ Time Frame: 12 months ]Fusion is defined as the presence of bridging trabecular bone and less than 3mm of translational motion and less than 5mm of angular motion.
- Number of participants with improvement in physical disability [ Time Frame: 12 months ]
- Number of participants with improvement in quality of life [ Time Frame: 12 months ]
- Number of participants with improvement in pain scores [ Time Frame: 12 months ]
- Number of participants with decreased usage of pain medication [ Time Frame: 12 months ]
- Returning to work [ Time Frame: 12 months ]
- Satisfaction with surgery [ Time Frame: 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01829997
|United States, New York|
|Hospital for Joint Disease|
|New York, New York, United States, 10003|
|Hospital for Special Surgery|
|New York, New York, United States, 10021|
|United States, South Carolina|
|MUSC Neurosurgery & Spine Services|
|Charleston, South Carolina, United States, 29425|
|United States, Wisconsin|
|Milwaukee Spinal Specialists|
|Glendale, Wisconsin, United States, 53212|
|Principal Investigator:||Stephen Robbins, MD||Milwaukee Spinal Specialists|